In May 2013, Next Pharmaceuticals purchased the worldwide distribution rights along with all patents, trademarks and scientific knowledge of Sytrinol from KGK Synergize. In a clinical trial measuring the serum bioavailability of Sytrinol, softgels manufactured by Soft Gel Technologies, Inc. exhibited enhanced bioavailability of the key active ingredients—specifically, the two polymethoxylated flavones tangeretin and nobiletin - compared to powder-filled, two-piece hard shell capsules.
“We are pleased to partner with Next Pharmaceuticals in promoting Sytrinol softgels,” noted Steve Holtby, president and CEO of Soft Gel Technologies, Inc. “Cardiovascular disease is not a small problem in America. Manufacturing a heart-health product that is sourced from natural plant compounds, patented and backed by science aligns with our company’s mission for providing high-quality, clinically-studied branded ingredients. Next Pharmaceuticals is a respected raw material supplier, who also invests in its brands and the science supporting its products.”
SGTI and Next Pharmaceuticals will not only work together to deliver Sytrinol softgels, but also to double marketing efforts to increase consumer awareness of the Sytrinol product and its potential health benefits.